Bal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2026 ,inter alia, to consider and approve Unaudited standalone and consolidated ....
BALPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bal Pharma Ltd has informed the stock exchanges that its Board of Directors will meet on Wednesday, February 11, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter ended December 31, 2025 (Q3 FY26). The notice was filed under SEBI's Listing Obligations and Disclosure Requirements (LODR) Regulation 29. The company has also announced that the trading window for designated persons and their immediate relatives is closed from January 1, 2026, until February 16, 2026 (48 hours after results declaration). No financial figures or business details have been disclosed in this filing.
This is a routine procedural filing with no direct impact on shareholders or stock price. Investors should watch for the actual Q3 FY26 results on February 11, 2026, which could move the stock depending on the numbers reported.